<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>Investing in Oncology: 3 Cancer Stocks With Promising Pipelines — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Investing in Oncology: 3 Cancer Stocks With Promising Pipelines</h2>
    <div class="badge">2025-09-08T13:42:00+00:00</div>
    <ul>
      <li>Preliminary data from monotherapy expansion cohorts of the study are expected in the second half of 2025 and in 2026.</li>
<li>Relay Therapeutics has a Zacks Rank #2 (Buy).</li>
<li>Today, you can download 7 Best Stocks for the Next 30 Days.</li>
<li>You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.</li>
<li>As per the American Cancer Society, the United States alone is expected to see 2,041,910 new cancer cases and 618,120 cancer-related deaths in 2025.</li>
<li>A phase I study has been initiated in patients with R/M HNSCC and other advanced solid tumors, with preliminary data expected in the second half of 2025.</li>
<li>Explore 30 cutting-edge investment themes with Zacks Thematic Screensand uncover your next big opportunity.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=Investing in Oncology: 3 Cancer Stocks With Promising Pipelines\n• Preliminary data from monotherapy expansion cohorts of the study are expected in the second half of 2025 and in 2026.\n• Relay Therapeutics has a Zacks Rank #2 (Buy).\n• Today, you can download 7 Best Stocks for the Next 30 Days.\n• You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\n• As per the American Cancer Society, the United States alone is expected to see 2,041,910 new cancer cases and 618,120 cancer-related deaths in 2025.\n• A phase I study has been initiated in patients with R/M HNSCC and other advanced solid tumors, with preliminary data expected in the second half of 2025.\n• Explore 30 cutting-edge investment themes with Zacks Thematic Screensand uncover your next big opportunity." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/investing-oncology-3-cancer-stocks-134200392.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>